KAMIREN

This brand name is authorized in Croatia, Estonia, Hong Kong SAR China, Ireland, Lithuania, Poland, Romania.

Active ingredients

The drug KAMIREN contains one active pharmaceutical ingredient (API):

1	Doxazosin UNII 86P6PQK0MU - DOXAZOSIN MESYLATE
	Doxazosin is a potent and selective post-junctional alpha-1-adrenoceptor antagonist. This action results in a decrease in systemic blood pressure.
	Read more about Doxazosin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
KAMIREN Prolonged-release tablet	MPI, EU: SmPC	Health Products Regulatory Authority (IE)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C02CA04	Doxazosin	C Cardiovascular system → C02 Antihypertensives → C02C Antiadrenergic agents, peripherally acting → C02CA Alpha-adrenoreceptor antagonists
Discover more medicines within C02CA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1071379, 1071380, 1071391, 1156261, 1156272, 1156283, 1156294
HK	Department of Health Drug Office	60181
HR	Agencija za lijekove i medicinske proizvode	HR-H-366773352, HR-H-708601380, HR-H-868744606
IE	Health Products Regulatory Authority	14585
LT	Valstybinė vaistų kontrolės tarnyba	1003365, 1003366, 1004329, 1019586, 1019587, 1019588, 1019589, 1019790, 1019791, 1019792
PL	Rejestru Produktów Leczniczych	100094653, 100094660, 100120847
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W08648001, W08648002, W08649001, W08649002